Research Topics
| Silvana MartinoSummaryAffiliation: Cancer Institute Medical Group Country: USA Publications
| Collaborators
|
Detail Information
Publications
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneSilvana Martino
Cancer Institute Medical Group, 2001 Santa Monica Blvd, Ste 560W, Santa Monica, CA 90404, USA
J Natl Cancer Inst 96:1751-61. 2004..We conducted the Continuing Outcomes Relevant to Evista (CORE) trial to examine the effect of 4 additional years of raloxifene therapy on the incidence of invasive breast cancer in women in MORE who agreed to continue in CORE...- Safety assessment of raloxifene over eight years in a clinical trial settingSilvana Martino
The Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
Curr Med Res Opin 21:1441-52. 2005..The aim of this study was to assess the safety of raloxifene over 8 years in 4011 postmenopausal women with osteoporosis in a clinical trial setting through adverse event reporting... - The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trialsSilvana Martino
The John Wayne Cancer Institute, St. Johns Health Center, Santa Monica, California, USA
Oncologist 9:116-25. 2004..Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction... 
Prognostic value of basal phenotype in HER2-overexpressing breast cancerSanjay P Bagaria
Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA
Ann Surg Oncol 19:935-40. 2012..We investigated the clinical relevance of this basal-HER2+ subtype within HER2-overexpressing breast tumors...- Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal womenOlga M Olevsky
Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
Menopause 15:790-6. 2008..It has a more favorable toxicity profile than tamoxifen and provides an alternative for postmenopausal women... - Prediction of breast tumor progression by integrity of free circulating DNA in serumNaoyuki Umetani
Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
J Clin Oncol 24:4270-6. 2006..0002 and P < .0001, respectively). CONCLUSION: Integrity of serum circulating DNA is a promising molecular biomarker for detecting breast cancer tumor progression and regional LN metastases... - A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss
Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
N Engl J Med 349:1793-802. 2003..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy... - Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer riskMarc E Lippman
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
Clin Cancer Res 12:5242-7. 2006..To assess the effect of raloxifene, indicated for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women defined by risk factors for breast cancer... - Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17Edith A Perez
St Michael s Hospital, Toronto, Canada
J Clin Oncol 24:3629-35. 2006..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen... - Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Breast Cancer Res Treat 99:295-300. 2006..CONCLUSION: These analyses suggest that, at least out to about 48 months, longer duration of letrozole treatment is associated with greater benefit in the extended adjuvant therapy setting... - Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal womenTimothy J Whelan
McMaster University, Hamilton, Canada
J Clin Oncol 23:6931-40. 2005..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial... - Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)Nancy E Davidson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
J Clin Oncol 23:5973-82. 2005..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established... - Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17Hyman B Muss
University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
J Clin Oncol 26:1956-64. 2008..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women... - Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss
Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
J Clin Oncol 26:1948-55. 2008..When the trial was unblinded, patients who received placebo (PLAC) were offered LET... - Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratorySunil S Badve
Eastern Cooperative Oncology Group, Boston, MA, USA
J Clin Oncol 26:2473-81. 2008.... 
Weekly paclitaxel in the adjuvant treatment of breast cancerJoseph A Sparano
Eastern Cooperative Oncology Group, Philadelphia, USA
N Engl J Med 358:1663-71. 2008..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...- Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626J Wendall Goodwin
Cancer Research for the Ozarks, 1730 E Republic Rd, Suite V, Springfield, MO 65804, USA
J Clin Oncol 26:1650-6. 2008..Prior progestin studies treating hot flashes in women have been short duration and single dose. This study tests the progestin megestrol acetate (MA) at two doses versus placebo over 6 months... - Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623Halle C F Moore
Cleveland Clinic Foundation, Cleveland, OH, USA
J Clin Oncol 25:1677-82. 2007.... - Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss
Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
J Clin Oncol 25:2006-11. 2007..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status... - Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrenceCarolyn Cook Gotay
Cancer Research Center of Hawaii, Honolulu, HI 96822, USA
J Clin Oncol 25:2093-9. 2007..The Southwest Oncology Group conducted a phase III randomized trial to evaluate the effectiveness of a brief telephone intervention... - HER2 and response to paclitaxel in node-positive breast cancerDaniel F Hayes
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
N Engl J Med 357:1496-506. 2007..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both... - Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresLori J Goldstein
Eastern Cooperative Oncology Group, Boston, MA, USA
J Clin Oncol 26:4063-71. 2008..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features... - Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Lori J Goldstein
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
J Clin Oncol 26:4092-9. 2008..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer... - Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialEdith A Perez
Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 26:1231-8. 2008..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial... - Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897Patricia A Ganz
School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 650 Charles Young Dr South, Room A2 125 CHS, Los Angeles, CA 90095 6900, USA
J Clin Oncol 26:1223-30. 2008..The late cardiac effects of adjuvant anthracycline therapy in survivors of early-stage breast cancer have had limited study. Subclinical and clinical cardiac late effects may contribute to added comorbidity over time... - Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden
Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
J Clin Oncol 25:656-61. 2007.... - HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trialEdith A Perez
Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 24:3032-8. 2006..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab... - Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results ofSaul E Rivkin
Swedish Cancer Institute, Seattle, Washington, USA
Cancer 97:21-9. 2003..CONCLUSIONS: The authors conclude that, after 20 years of follow-up, adjuvant chemotherapy with CMFVP remains superior to L-PAM for the treatment of patients with lymph node positive breast carcinoma... - Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)George W Sledge
Cancer Pavillion, Indiana University Medical Center, 535 Barnhill Drive, Room RT473, Indianapolis, IN 46202 5112, USA
J Clin Oncol 21:588-92. 2003..Patients receiving single-agent doxorubicin or paclitaxel were crossed over to the other agent at time of progression... - Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatmentNancy Ellerbroek
Providence Holy Cross Cancer Center, Los Angeles, California, USA
Breast J 9:74-8. 2003..Additional study is needed to determine optimal timing, long-term toxicity, and potential benefits of concurrent radiation therapy and paclitaxel... - Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerI Craig Henderson
University of California at San Francisco, San, Francisco, CA 94143, USA
J Clin Oncol 21:976-83. 2003..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival... - Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and LeukemiaMarc L Citron
ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
J Clin Oncol 21:1431-9. 2003.... - A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancerGary H Lyman
James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642 0001, USA
Breast Cancer Res Treat 85:143-50. 2004..To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial... - Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup studyLorie L Hughes
Department of Radiation Oncology, WellStar Kennestone Hospital, Marietta, GA 30060, USA
Cancer 101:969-72. 2004..In the current study, we report the efficacy of pelvic RT with this dose-fractionation scheme in the induction of ovarian ablation... - HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group studyGrazia Arpino
Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
Clin Cancer Res 10:5670-6. 2004.... - Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialEdith A Perez
North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
J Clin Oncol 22:3700-4. 2004.... - Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss
Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
J Natl Cancer Inst 97:1262-71. 2005..This report presents updated findings from the trial... - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010Laura F Hutchins
University of Arkansas for Medical Sciences, Little Rock, AR, USA
J Clin Oncol 23:8313-21. 2005..05). CONCLUSION: CAF did not improve DFS compared with CMF; there was a slight effect on OS. Given greater toxicity, we cannot conclude CAF to be superior to CMF. TAM is effective in HR-positive disease, but not in HR-negative disease... - Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry
University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
JAMA 295:1658-67. 2006..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy... - Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831Patrick C Roche
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
J Natl Cancer Inst 94:855-7. 2002..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...